Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific ADC in Extensive-Stage Small Cell Lung Cancer – Journal of Clinical Oncology.
M=52 Phase 1B
- ORR: 48.1%; median PFS: 4.1 mo; median OS: 12.2 mo
- 2L patients: ORR 72.7%, PFS 6.2 mo, OS 15.0 mo
- Most common toxicities: neutropenia, thrombocytopenia, anemia & leukopenia
- HER3 expression may be associated with better response.
- A promising bispecific ADC approach targeting EGFR + HER3 in SCLC.”
Title: Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
Authors: Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang.
Read the full article.
You might be interested in: Izalontamab Brengitecan Shows Encouraging Activity in Relapsed ES-SCLC
